Literature DB >> 31833846

Immunotherapy for Gynecologic Cancer: Current Applications and Future Directions.

Sarah Lynam1, Amit A Lugade2, Kunle Odunsi1,2.   

Abstract

The role of the immune system in the development of cancer has been a subject of ongoing clinical investigation in recent years. Emerging data demonstrate that tumorigenesis resulting in ovarian, uterine, and cervical cancers is a consequence of impaired host immune responses to cancerous cells. Leveraging the immune system through the use of immune checkpoint inhibitors, therapeutic vaccine therapy, and adoptive cell transfer presents a profound opportunity to revolutionize cancer treatment. This review will encompass the role of the immune system in development of gynecologic cancers and highlight recent data regarding immunotherapy applications in ovarian, uterine, and cervical cancers.

Entities:  

Mesh：

Year:  2020        PMID： 31833846      PMCID： PMC7298668          DOI： 10.1097/GRF.0000000000000513

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN： 0009-9201            Impact factor:   1.966


  88 in total

1.  Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.

Authors:  P G Rose; B N Bundy; E B Watkins; J T Thigpen; G Deppe; M A Maiman; D L Clarke-Pearson; S Insalaco
Journal:  N Engl J Med       Date:  1999-04-15       Impact factor: 91.245

2.  Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.

Authors:  U A Matulonis; R Shapira-Frommer; A D Santin; A S Lisyanskaya; S Pignata; I Vergote; F Raspagliesi; G S Sonke; M Birrer; D M Provencher; J Sehouli; N Colombo; A González-Martín; A Oaknin; P B Ottevanger; V Rudaitis; K Katchar; H Wu; S Keefe; J Ruman; J A Ledermann
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

3.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.

Authors:  Dung T Le; Jennifer N Uram; Hao Wang; Bjarne R Bartlett; Holly Kemberling; Aleksandra D Eyring; Andrew D Skora; Brandon S Luber; Nilofer S Azad; Dan Laheru; Barbara Biedrzycki; Ross C Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Steven M Duffy; Richard M Goldberg; Albert de la Chapelle; Minori Koshiji; Feriyl Bhaijee; Thomas Huebner; Ralph H Hruban; Laura D Wood; Nathan Cuka; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; Shibin Zhou; Toby C Cornish; Janis M Taube; Robert A Anders; James R Eshleman; Bert Vogelstein; Luis A Diaz
Journal:  N Engl J Med       Date:  2015-05-30       Impact factor: 91.245

4.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells.

Authors:  P Brossart; S Wirths; G Stuhler; V L Reichardt; L Kanz; W Brugger
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

5.  Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.

Authors:  E García-Hernández; J L González-Sánchez; A Andrade-Manzano; M L Contreras; S Padilla; C C Guzmán; R Jiménez; L Reyes; G Morosoli; M L Verde; R Rosales
Journal:  Cancer Gene Ther       Date:  2006-06       Impact factor: 5.987

6.  Two pathogenetic types of endometrial carcinoma.

Authors:  J V Bokhman
Journal:  Gynecol Oncol       Date:  1983-02       Impact factor: 5.482

7.  Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.

Authors:  Amorette Barber; Tong Zhang; Charles L Sentman
Journal:  J Immunol       Date:  2008-01-01       Impact factor: 5.422

8.  Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer.

Authors:  R A de Jong; N Leffers; H M Boezen; K A ten Hoor; A G J van der Zee; H Hollema; H W Nijman
Journal:  Gynecol Oncol       Date:  2009-05-02       Impact factor: 5.482

Review 9.  Translational implications of tumor heterogeneity.

Authors:  Mariam Jamal-Hanjani; Sergio A Quezada; James Larkin; Charles Swanton
Journal:  Clin Cancer Res       Date:  2015-03-15       Impact factor: 12.531

10.  A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes.

Authors:  P F Robbins; M El-Gamil; Y F Li; Y Kawakami; D Loftus; E Appella; S A Rosenberg
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307
View more
  4 in total

Review 1.  Emerging role of circulating tumor cells in immunotherapy.

Authors:  Alexey Rzhevskiy; Alina Kapitannikova; Polina Malinina; Arthur Volovetsky; Hamidreza Aboulkheyr Es; Arutha Kulasinghe; Jean Paul Thiery; Anna Maslennikova; Andrei V Zvyagin; Majid Ebrahimi Warkiani
Journal:  Theranostics       Date:  2021-07-06       Impact factor: 11.556

Review 2.  Immunotherapy in Ovarian Cancer.

Authors:  Natalia Siminiak; Rafał Czepczyński; Mikołaj Piotr Zaborowski; Dariusz Iżycki
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2022-08-09       Impact factor: 3.831

3.  Immune Cytolytic Activity for Comprehensive Insights of the Immune Landscape in Endometrial Carcinoma.

Authors:  Qiang Chen; Chongyang Wang; Xinyi Lei; Ting Huang; Renyu Zhou; Yuanzhi Lu
Journal:  J Oncol       Date:  2022-07-18       Impact factor: 4.501

Review 4.  Dendritic Cell Vaccines: A Promising Approach in the Fight against Ovarian Cancer.

Authors:  Aarushi Audhut Caro; Sofie Deschoemaeker; Lize Allonsius; An Coosemans; Damya Laoui
Journal:  Cancers (Basel)       Date:  2022-08-21       Impact factor: 6.575
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.